- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Tahir Amin: Ongoing Work in Challenging Drug Patents
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses his organization's ongoing work in challenging drug patents.
Transcript:
What are some of the cases you’re working on now?
So one of the major cases we’re working on is Sofosbuvir, branded as Sovaldi. It’s a hepatitis C drug, and currently we filed 10 IPRs last year in the United States [Patent Trial and Appeal Board, PTAB]. Currently, we’re waiting to hear whether those will be instituted, and by instituted, I mean whether the PTAB will take those cases on and will go into trial.
We have a number of cases going on in India involving hepatitis C drugs, and in China we already had some successful decisions.
The importance of these cases is to show that a lot of people are still not getting these new, direct-acting anti-viral hepatitis C drugs, and we feel that our work is to try and create an opportunity for people lacking access to get them.
Also, in the United States, a lot of people living with hepatitis C are not getting the treatment that they need, and I hope the cases we have brought will leverage some opportunities to try and get these drugs at more affordable prices, because only 1% of the number of Americans that need the drug are getting it at the moment.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
